| Organ system | Age-related change | Potential CRC relevance |
| Bone Marrow | ↓ Cellularity and reserve | ↑ Risk of leukopenia: dose reduction and growth factor often needed |
| Liver | ↓ Parenchymal volume | Less able to tolerate oxaliplatin steatohepatitis, metastasectomy |
| Kidney | ↓ Glomerular filtration rate | ↑ Risk of prerenal azotemia |
| Cardiovascular | ↑ CAD, valvular disease, HTN |
Fluoropyrimidine coronary vasospasm Greater risk from bevacizumab-related hypertension and arterial thromboembolism |
| Central nervous system |
↓ Cerebral perfusion ↑ Autonomic disturbance |
5-FU-associated cerebellar toxicity, with greater effect on balance, gait |
